US Pharmaceutical Company Eli Lilly Requests Emergency Use Authorization for COVID-19 Treatment from FDA

Request for Approval of 'LY-CoV555' for Mild Patients... "Prevents Worsening to Severe"
WSJ "Likely to Be the First Treatment for Patients with Mild Symptoms"

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Jeong Hyunjin] U.S. pharmaceutical company Eli Lilly has applied for emergency use authorization from the U.S. Food and Drug Administration (FDA) for its antibody treatment for COVID-19, according to reports by The Wall Street Journal (WSJ) and others on the 7th.

According to the reports, Eli Lilly announced that it has applied for emergency use authorization for its antibody treatment 'LY-CoV555.' This treatment is intended for use in patients with mild symptoms, and Eli Lilly stated that it seeks approval to use it for high-risk groups such as elderly people over 65 and obese patients.

Eli Lilly explained that its antibody treatment can prevent mild patients from worsening to the point of hospitalization. WSJ reported, "If approved, this would be the first drug available for cases with less severe COVID-19 symptoms." Previously used COVID-19 treatments like Gilead Sciences' Remdesivir were primarily used for patients with severe symptoms requiring hospitalization.

Eli Lilly stated that this treatment alleviates COVID-19 symptoms and reduces hospitalization rates. Last month, Eli Lilly announced research results showing that the rate of hospitalization or emergency room visits among patients treated with this drug was only 1.6%, significantly lower than the 5.8% hospitalization rate of untreated patients.

On this day, Eli Lilly explained that when this treatment was administered together with another antibody treatment, 'LY-CoV016,' the amount of virus present in the body significantly decreased from the 11th day, and no serious side effects were observed. Eli Lilly also announced plans to apply for approval for the combined treatment soon. If granted emergency use authorization, Eli Lilly said it could manufacture 100,000 doses this month and 1 million doses within this year.

Following the news that Eli Lilly requested emergency use authorization from the FDA for its COVID-19 treatment, its stock price closed at 148.96, up 3.35% on the New York Stock Exchange that day.

Meanwhile, former U.S. President Donald Trump, who was diagnosed with COVID-19, received emergency use authorization from the FDA for an antibody treatment developed by Eli Lilly's competitor Regeneron and returned to the White House three days after hospitalization.

This content was produced with the assistance of AI translation services.